# IMed Technologies Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/imed-technologies-co

- Industry: Software
- Headquarters: Tokyo, Japan
- Website: www.imed-tech.co.jp
- Total disclosed funding: $1.6M
- Latest round: Series A (Oct 1, 2020)
- Investors on record: 3

## About

IMed Technologies Co., Ltd. is focused on developing advanced medical imaging analysis software aimed at enhancing the safety and precision of neurovascular surgeries. Their flagship product, Neuro-Vascular Assist, utilizes machine learning to support surgical procedures.Founded in 2019 in Tokyo, Japan, IMed Technologies Co., Ltd. specializes in innovative medical imaging solutions. The company raised JPY 170 million in Series A funding on October 1, 2020, with investments from Globis Capital Partners, Mitsui Sumitomo Insurance, and SBI Investment. Kenichi Kono currently serves as CEO, while Motohisa Kaneko is the founder.IMed Technologies, Inc. specializes in the development and sale of medical imaging analysis software, particularly its flagship product, Neuro-Vascular Assist. This software is designed to enhance the safety and effectiveness of neurovascular surgeries, offering real-time support and analysis to assist surgeons during procedures. The company serves hospitals and healthcare institutions that conduct neurovascular surgeries, primarily targeting markets in Japan and expanding into regions with established neurointerventional practices.The revenue model of IMed Technologies revolves around the sale and licensing of its medical imaging software, Neuro-Vascular Assist. This typically involves direct partnerships with healthcare providers under subscription-based licensing agreements, ensuring ongoing software updates and support. Clients, including hospitals and surgical centers, utilize these agreements to access advanced tools that improve surgical precision and contribute to better patient outcomes in neurovascular interventions.IMed Technologies plans to leverage the recent JPY 170 million raised in Series A funding to support the development of new products and expand into additional markets. The funding will facilitate advancements in their existing software and potential new offerings aimed at enhancing neurovascular care. The company is targeting expansion into broader Asian markets and seeks to establish a stronger presence in regions with a high demand for neurointerventional surgeries by 2023.

## Funding rounds

- Series A, Oct 1, 2020, $1.6M — Mitsui Sumitomo Insurance, Globis Capital Partners, SBI Investment

## Investors

- Mitsui Sumitomo Insurance — Series A
- Globis Capital Partners (https://capitalatlas.ai/funds/globis-capital-partners) — Series A
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A